At the heart of much supposed “controversy” in endocrinology is the role of T3 thyroid hormone testing and T3-based treatments for hypothyroidism.
Perpetuating this “controversy” is the continual restatement in research articles that T3 and T4-T3 combination therapy (of which Natural Dessicated Thyroid is a sub-type) is a “controversy.” Repeatedly saying it is controversial only serves to reinforce the controversy and dismisses it, if the persons stating it are not doing anything to resolve it.
Meanwhile, clinical practice shows little sign of an actively debated controversy. Most doctors conform to the T4-only recommendations for best practice because they are easy and cheap. Adjusting Synthroid dosage to TSH levels to “normalize the TSH” has turned into a simple game of numbers that leaves many hypothyroid patients symptomatic and at risk.
As I show in my review of a journal article by Abdalla & Bianco (2014), biology teaches that a healthy plasma T3 level must be defended, and the TSH cannot be trusted to indicate adequate T3 levels.
The dangers of low-T3 in any patient can be logically hypothesized from many studies of “Low T3 Syndrome” and “Sick Euthyroid Syndrome” and “subclinical hypothyroidism”
A recent journal article (Rhee, et al, 2015) included a table outlining the associations between Low T3 and morbidity/mortality: Continue reading “The dangers of Low T3”